Diabetes, a chronic disease posing an escalating threat to global health, has seen a worrying increase in recent decades. With over 420 million affected individuals worldwide, the associated disease burden has significantly risen, with a 70% increase in mortality in just 20 years.
Halting the rise of diabetes requires strategies focused on prevention, timely diagnosis, monitoring and control of risk factors, and appropriate treatment. In this regard, Heberprot-P®, Cuba's unique revolutionary medication, stands out as a tool in the fight against one of diabetes' most common and feared neurovascular complications: diabetic foot ulcers.
Developed by the Center for Genetic Engineering and Biotechnology, Heberprot-P® is a lyophilized product containing recombinant human epidermal growth factor. Administered by specialized professionals from the Institute of Angiology and Vascular Surgery and the Institute of Endocrinology, this treatment has shown to stimulate granulation and progressive healing, reduce the need for surgical interventions, minimize recurrences and healing time, decrease hospital costs, improve quality of life and functional recovery, and reduce infection risks.
The comprehensive medical program offers an initial assessment including consultations with specialists, complementary investigations, and procedures to prepare the areas to be treated with the medication. The second stage involves medication treatment, where infiltration with Heberprot-P® is performed on the lesions.
In a world seeking effective solutions to combat diabetes and its complications, Cuban medical advancements offer hope and a path towards a healthier life for those affected by this disease. Those interested in this treatment can contact the Coordination and Processing Center of the Comercializadora de Servicios Médicos Cubanos, S.A., via email at smc@smcsalud.cu.
Together, we can combat diabetes complications and improve the quality of life for millions worldwide.
By: MSc. Dra. Patricia Alonso Galbán
Marketing and Communication Specialist, CSMC, S.A.